Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 257

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 257
---
 the Series E Warrants, the December 2023 Private Placement Pre-Funded Warrants, December Public Offering Pre-Funded Warrants and the December 2023 Underwriter Warrants.All Series F Warrants in the offering have either been exercised or have expired.

Exercisability.
The warrants became exercisable on December 21, 2023. The Series E Warrants and December 2023Underwriter
Warrants expire five years and three years, respectively from the initial exercise date. The December 2023 Private Placement Pre-Funded Warrants and December Public Offering Pre-Funded Warrants are exercisable at any time and do not expire. The holder shall deliver the aggregate exercise price for the Depositary
Shares specified in the exercise notice within two trading days following the date of exercise (subject to the ‘cashless exercise’
arrangements described below).

Cashless Exercise. If, at the time a holder exercises its Series E Warrants, a registration statement registering the issuance of
the securities underlying the Series E Warrants under the Securities Act is not then effective or available and an exemption from
registration under the Securities Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise
contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon
such exercise (either in whole or in part) the net number of Depositary Shares determined according to a formula set forth in the Series E
Warrants.

At
the time a holder exercises its December 2023 Private Placement Pre-Funded Warrants
or December Public Offering Pre-Funded Warrants, in lieu of making the cash payment
otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to
receive upon such exercise (either in whole or in part) the net number of Depositary Shares determined according to a formula set forth
in the December 2023 Private Placement Pre-Funded Warrants or December Public Offering Pre-Funded Warrants, as applicable.

Exercise Price.The exercise price of each Series E Warrant, December 2023Underwriter
Warrant, December 2023 Private Placement Pre-Funded Warrant and December Public Offering Pre-Funded Warrants is $55.00, $62.50, $0.0025 and $0.0025 per Depositary Share.

Beneficial Ownership Limitation. A holder shall have no right to exercise any portion